I think page 3 of the investor update is referring to the...

I think page 3 of the investor update is referring to the following announcement from a fortnight ago:

Cxbladder Monitor Significantly Outperforms All Compared FDA Approved Urine Tests For Bladder Cancer; Enhancing The Standard Of Care For Bladder Cancer Patients (Click here)

This should provide Cellmid with further licensing fees in the next few years, particularly if CxBladder is being picked up as the de-facto standard test. In this context, I particularly like the first paragraph of page 2 in the Investor update:

This choice of words ('where', not 'if'), shows confidence, and with such outperformance of comparable tests, I can see why. While Pacific Edge is not Cellmid, the success of CxBladder shows how a single indication for midkine as a biomarker can generate revenue for Cellmid, where there are potentially many following, such as the recently mentioned mesothelioma.

It is nice to know too that Cellmid is invested in Pacific Edge with over a million shares.